Dorzolamide + Timolol
Dosage Form: Opthalmic solution.
This Eye Drops is indicated for the treatment of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta blockers.
Dorzolamide, a carbonic anhydrase inhibitor, has actions similar to acetazolamide. By inhibiting carbonic anhydrase in the ciliary processes of the eye, dorzolamide decreases aqueous humor secretion. Used together, there is additional intraocular pressure reduction compared to using either component alone, but the reduction is not as much as concomitant admin of dorzolamide tid and timolol bid.
Timolol maleate, a nonselective β-adrenergic blocker, reduces aqueous humor formation.
Instill one drop in the conjunctival sac of the affected eye(s) twice daily.
Route of administration: Intra ocular.
Oral calcium channel blockers, catecholamine-depleting medicines or -blockers, antiarrhythmics (e.g. amiodarone), digitalis glycosides, parasympathomimetics, opioids, and MAOIs cause additive hypotension and bradycardia. Oral carbonic anhydrase or -blockers have additive systemic adverse effects; avoid using them together. CYP2D6 inhibitors (e.g. quinidine, SSRIs) and timolol in combination for systemic -blockade.
Contraindicated in patients who are hypersensitive to any of the components of this preparation.
Mild burning, ocular hyperemia, and impaired vision are all possible side effects.
Pregnancy & Lactation:
Pregnancy: No suitable and well-controlled trials have been conducted in pregnant women. During pregnancy, these Eye Drops should only be used if the potential benefit outweighs the potential risk to the fetus.
When administering This Eye Drops to a breastfeeding mother, extreme caution should be observed.
Precautions & Warnings:
Only for ophthalmic use. Patients should remove their contact lenses before using this preparation and wait 15 minutes before putting them back in.
Drugs for miotics and glaucoma.
Store between 15-30°C. Protect from light.
Manufactured by: Aristopharma Ltd.